Gilead Dips on 23% Volume Drop to 141st Rank Yet Holds Near 52-Week High as Analysts Hike Targets to $140-$143

Gilead Sciences (GILD) closed at a 0.37% decline on August 12, 2025, with a trading volume of $730 million, a 23.24% drop from the previous day, ranking it 141st in market activity. The stock, however, remains near a 52-week high of $121.67, reflecting a 70.37% annual gain. Analysts highlighted the company’s robust second-quarter performance, reporting $7.1 billion in revenue and $1.97 earnings per share, driven by strong HIV drug sales. This outperformance prompted several brokerages to raise price targets, with BofA Securities and Morgan Stanley setting new benchmarks at $140 and $143 respectively.

Investor confidence in Gilead is underscored by its "GREAT" financial health rating, a $150 billion market capitalization, and a 78.5% gross profit margin. The biopharmaceutical giant has consistently delivered dividend growth over the past decade, reinforcing its position as a key player in the biotech sector. Analysts emphasized the HIV segment as a critical growth driver, with revenue reaching $7.08 billion in the quarter. Truist Securities upgraded the stock to a Buy rating, citing improved full-year guidance and sustained momentum in core product lines.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day yielded a total profit of $2,340 from 2022 to the present. However, the approach faced a maximum drawdown of -15.3% on October 27, 2022, highlighting the inherent risks of short-term trading strategies in volatile markets.